Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
protein degradation
Biotech
French biotech pens $128M deal for Kezar protein degrader work
French biotech Enodia is paying $1 million upfront in a back-loaded deal for Kezar Life Sciences’ preclinical protein degradation program.
James Waldron
Mar 12, 2026 9:00am
Cullgen ditches reverse merger with Pulmatrix to go with Gyre
Mar 2, 2026 10:55am
J&J, Google venture arms line up to back EpiBiologics' series B
Jan 8, 2026 9:05am
Amgen weaves in UK biotech with up to $840M acquisition
Jan 6, 2026 10:35am
Amphista's targeted glue sticks the landing in early AML test
Dec 8, 2025 7:40am
Nurix trims staff as trial for lead BTK degrader kicks off
Nov 21, 2025 5:05am
